Cargando…

A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With α-Blockers and α-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction

PURPOSE: Combination therapy with an α-1-adrenergic blocker and phosphodiesterase type 5 inhibitors (PDE5Is) has shown improvements in lower urinary tract symptoms (LUTS) with negligible side effects. Nonetheless, decisive advantages in symptom improvement were insufficient, and there were no clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Hoon, Kim, Hyun Jung, Bae, Jae Hyun, Kim, Jae Heon, Moon, Du Geon, Cheon, Jun, Yeo, Jeong-Kyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Continence Society 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703931/ https://www.ncbi.nlm.nih.gov/pubmed/26739178 http://dx.doi.org/10.5213/inj.2015.19.4.237

Ejemplares similares

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis
por: Kim, Hyun Jung, et al.
Publicado: (2017)

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men
por: Matsuo, Tomohiro, et al.
Publicado: (2016)

Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis
por: Qiangzhao, Liu, et al.
Publicado: (2020)

The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
por: Byun, Ja Min, et al.
Publicado: (2015)

Alpha-1 Adrenergic Receptor Blockers for the Treatment of Lower Urinary Tract Symptoms in Women: A Systematic Review and Meta-Analysis
por: Kim, Do Kyung, et al.
Publicado: (2019)

CNS Demyelination with TNF-α Blockers
por: Kemanetzoglou, Elissavet, et al.
Publicado: (2017)

Who are suitable for low-dose tamsulosin monotherapy as initial treatment strategy in male patients with lower urinary tract symptoms?
por: Kim, Jae Heon, et al.
Publicado: (2018)

Personalized therapeutics of α(1)-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Zhu, Ling-ling, et al.
Publicado: (2015)

α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
por: Roehrborn, Claus G., et al.
Publicado: (2016)

Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
por: Moon, Hyong Woo, et al.
Publicado: (2018)

Prostatic urethral angle might be a predictor of treatment efficacy of α-blockers in men with lower urinary tract symptoms
por: Hou, Chen-Pang, et al.
Publicado: (2014)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α(1)-Blockers
por: Kobayashi, Minoru, et al.
Publicado: (2017)

Efficacy and Safety of the Selective α(1A)-Adrenoceptor Blocker Silodosin for Severe Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Prospective, Single-Open-Label, Multicenter Study in Korea
por: Moon, Ki Hak, et al.
Publicado: (2014)

A Survey of the FAERS Database Concerning the Adverse Event Profiles of α1-Adrenoreceptor Blockers for Lower Urinary Tract Symptoms
por: Yoshimura, Koji, et al.
Publicado: (2013)

Effect of α1D-adrenoceptor blocker for the reduction of ureteral contractions
por: Hong, Seong Hwi, et al.
Publicado: (2023)

Analysis of Prescriptions of Alpha-Blockers and Phosphodiesterase 5 Inhibitors from the Urology Department and Other Departments
por: Kang, Dong Hyuk, et al.
Publicado: (2011)

Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis
por: Gu, Ki-Nam, et al.
Publicado: (2019)

Effect of the symptom-based alpha-blocker treatment on lower urinary tract symptoms in women: systematic review and meta-analysis
por: Kang, Tae Wook, et al.
Publicado: (2021)

Role of α1‐blockers in the current management of hypertension
por: Li, Hua, et al.
Publicado: (2022)

α-Adrenoceptor blockers and phaeochromocytoma surgery: outdated combination?( )
por: Gunnesson, Lisa, et al.
Publicado: (2022)

Behҫet’s Disease, and the Role of TNF-α and TNF-α Blockers
por: van der Houwen, Tim, et al.
Publicado: (2020)

Changes in autonomic nervous system activity after treatment with alpha-blocker in men with lower urinary tract symptoms
por: Shim, Kang Hee, et al.
Publicado: (2018)

Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis
por: Gwon, Yong Nam, et al.
Publicado: (2023)

Effect of α-receptor blockers on lower urinary tract symptoms, sexual function and quality of life in young and middle-aged men with benign prostatic hyperplasia
por: Wang, Tongqing, et al.
Publicado: (2017)

Effect of Calcium Channel Blockers on Lower Urinary Tract Symptoms: A Systematic Review
por: Salman, Muhammad, et al.
Publicado: (2017)

Effect of Patient-Optimized Doses of Tamsulosin on Erectile Function in Men With Erectile Dysfunction and Lower Urinary Tract Symptoms
por: Jo, Hyun Wook, et al.
Publicado: (2013)

Comparison of Effect of Leukotriene Biosynthesis Blockers and Inhibitors of Phosphodiesterase Enzyme in Patients with Bronchial Hyperreactivity
por: Morina, Naim, et al.
Publicado: (2018)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Terminal dribbling in male patients with lower urinary tract symptoms: relationship with International Prostate Symptom Score and with intravesical prostatic protrusion
por: Kim, Jae Heon, et al.
Publicado: (2015)

Regression of Intracranial Meningioma during Treatment with α(1)-Adrenoceptor Blocker
por: Hoegestoel, Einar August, et al.
Publicado: (2016)

Ten years of intraoperative floppy iris syndrome in the era of α-blockers
por: Lunacek, Andreas, et al.
Publicado: (2017)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

P2Y12 blocker monotherapy after percutaneous coronary intervention
por: Verheugt, F. W. A., et al.
Publicado: (2021)

The Effect of TNF-α Blocker HL036337 and Its Best Concentration to Inhibit Dry Eye Inflammation
por: Choi, Wungrak, et al.
Publicado: (2016)

Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
por: Son, Mijeong, et al.
Publicado: (2022)

Effects of Spinal and Peripheral Injection of α1A or α1D Adrenoceptor Antagonists on Bladder Activity in Rat Models with or without Bladder Outlet Obstruction
por: Kim, Jae Heon, et al.
Publicado: (2011)

Bladder Wall Thickness is Associated with Responsiveness of Storage Symptoms to Alpha-Blockers in Men with Lower Urinary Tract Symptoms
por: Park, Jung Soo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bnqnqfpfrrceoanafsrdpkeedq